Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.68, $1.13 better than the analyst estimate of $4.55. Revenue for the quarter came in at $2.78 billion versus the consensus estimate of $2.61 billion.

GUIDANCE:

Biogen sees FY2021 EPS of $17.50-$19.00, versus the consensus of $18.59. Biogen sees FY2021 revenue of $10.65-10.85 billion, versus the consensus of $10.63 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.